Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Eli Lilly Halts Development of Phase 2 Pain Candidate in Pipeline Shakeup

Eli Lilly Halts Development of Phase 2 Pain Candidate in Pipeline Shakeup

Eli Lilly has announced the discontinuation of its phase 2 P2X7 inhibitor, LY3857210, for pain indications, marking another significant shift in the company's pain pipeline this year. The decision comes as part of Lilly's ongoing efforts to streamline its research and development portfolio.

NoahAI News10/31/2025
Bristol Myers Squibb Faces Challenges with Cobenfy Uptake Despite Strong Q3 Performance

Bristol Myers Squibb Faces Challenges with Cobenfy Uptake Despite Strong Q3 Performance

Bristol Myers Squibb (BMS) reported a robust third-quarter performance, with total revenue reaching $12.2 billion, surpassing analyst expectations. However, the pharmaceutical giant is grappling with slower-than-anticipated uptake of its newly approved schizophrenia drug, Cobenfy, while investors eagerly await critical trial results for its potential application in Alzheimer's disease psychosis.

NoahAI News10/30/2025
Biogen's Leqembi Shows Promise in Presymptomatic Alzheimer's, But Challenges Remain

Biogen's Leqembi Shows Promise in Presymptomatic Alzheimer's, But Challenges Remain

Biogen and its partner Eisai are making significant strides in the fight against Alzheimer's disease, with their anti-amyloid drug Leqembi showing potential for presymptomatic patients. However, the pharmaceutical giant faces hurdles in convincing doctors to adopt this paradigm-shifting approach to Alzheimer's treatment.

NoahAI News10/30/2025
Eli Lilly Announces $1.2B Investment in Puerto Rico for Oral Drug Manufacturing

Eli Lilly Announces $1.2B Investment in Puerto Rico for Oral Drug Manufacturing

Eli Lilly and Company has unveiled plans for a $1.2 billion investment to expand and modernize its manufacturing facility in Carolina, Puerto Rico. The investment, aimed at bolstering the company's capacity to produce oral medications, is part of Lilly's broader strategy to strengthen its domestic manufacturing capabilities.

NoahAI News10/30/2025
Kyverna's CAR T Therapy Shows Promising Results in Myasthenia Gravis, Advancing Autoimmune Applications

Kyverna's CAR T Therapy Shows Promising Results in Myasthenia Gravis, Advancing Autoimmune Applications

Kyverna Therapeutics has reported groundbreaking results from its Phase II study of KYV-101, a CAR T cell therapy for generalized myasthenia gravis (gMG), setting a new efficacy standard in the field and potentially revolutionizing treatment for this debilitating autoimmune condition.

NoahAI News10/30/2025
FDA Halts Intellia's Gene Therapy Studies Due to Severe Liver Toxicity

FDA Halts Intellia's Gene Therapy Studies Due to Severe Liver Toxicity

The U.S. Food and Drug Administration (FDA) has placed two of Intellia Therapeutics' Phase III studies under clinical hold following reports of life-threatening liver side effects in a patient. The regulatory action, disclosed in an SEC filing on Wednesday, impacts the MAGNITUDE and MAGNITUDE-2 trials evaluating the CRISPR-edited gene therapy nexiguran ziclumeran (nex-z) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN).

NoahAI News10/30/2025
Novo Nordisk Challenges Pfizer with $6.5B Bid for Obesity Biotech Metsera

Novo Nordisk Challenges Pfizer with $6.5B Bid for Obesity Biotech Metsera

In a surprising turn of events, Novo Nordisk has made an unsolicited $6.5 billion bid for obesity drug developer Metsera, challenging Pfizer's previously announced acquisition of the biotech firm. This move has sparked a fierce bidding war between two pharmaceutical giants, highlighting the industry's intense focus on the rapidly growing obesity treatment market.

NoahAI News10/30/2025
Zimmer Biomet Secures FDA Breakthrough Status for Innovative Infection-Fighting Hip Implant

Zimmer Biomet Secures FDA Breakthrough Status for Innovative Infection-Fighting Hip Implant

Zimmer Biomet, a leading medical device company, has achieved a significant milestone in its quest to reduce post-operative infections in joint replacement surgeries. The company recently announced that it has received breakthrough device status from the U.S. Food and Drug Administration (FDA) for its novel iodine-treated total hip replacement system.

NoahAI News10/30/2025
Medline Files for IPO, Seeking to Raise $5 Billion at $50 Billion Valuation

Medline Files for IPO, Seeking to Raise $5 Billion at $50 Billion Valuation

Medline, a leading provider of medical and surgical products, has filed for an initial public offering (IPO) in the United States, marking a significant milestone for the healthcare supply giant. The company, which has experienced substantial growth in recent years, aims to capitalize on its market position and expand its global footprint.

NoahAI News10/30/2025
For-Profit Hospitals Exceed Q3 Expectations, Driven by Medicaid Supplemental Payments

For-Profit Hospitals Exceed Q3 Expectations, Driven by Medicaid Supplemental Payments

Major for-profit hospital systems in the United States have reported strong third-quarter earnings, surpassing analysts' expectations. This surge in performance is largely attributed to increased revenue per case, with Medicaid supplemental payments playing a pivotal role.

NoahAI News10/30/2025
Sensei Biotherapeutics Halts Cancer Drug Development, Explores Strategic Alternatives

Sensei Biotherapeutics Halts Cancer Drug Development, Explores Strategic Alternatives

Sensei Biotherapeutics, a clinical-stage biotechnology company, has announced the discontinuation of its sole clinical-stage cancer drug and warned of impending layoffs as it grapples with financial constraints. The company is now exploring strategic alternatives, including potential asset sales or even a complete wind-down of operations.

NoahAI News10/30/2025
Lilly's Zepbound and Mounjaro Dominate Q3, Surpassing Keytruda in Sales

Lilly's Zepbound and Mounjaro Dominate Q3, Surpassing Keytruda in Sales

Eli Lilly's incretin-based medications for obesity and diabetes have delivered a groundbreaking performance in the third quarter of 2025, with combined sales of Zepbound and Mounjaro reaching $10.1 billion. This milestone marks a significant shift in the pharmaceutical landscape, as the duo has now surpassed Merck's cancer blockbuster Keytruda in quarterly revenue.

NoahAI News10/30/2025
«1...91011...67»